All In Biotech

Drug Trial Radar · NCT03495882

A Study of Zalifrelimab and Balstilimab for Treatment of Participants With Metastatic or Locally Advanced Solid Tumors, and Expansion Into Select Solid Tumors (Cervical)

A Phase 1/2, Open-Label, Multi-Arm Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of AGEN1884 in Combination With AGEN2034 in Subjects With Metastatic or Locally Advanced Solid Tumors, and Expansion Into Select Solid Tumors

Last checked: Nov 20, 2026Latest source record: Aug 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

175

Actual

Start

Dec 18, 2017

Primary completion

Jul 15, 2022

Study completion Jul 15, 2022

Sponsor

Lead sponsor
Agenus Inc.Industry
Sponsor type
Industry
First posted
Apr 12, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1/2, open-label study of zalifrelimab (AGEN1884) in combination with balstilimab (AGEN2034) in participants with locally advanced, recurrent and/or metastatic solid tumors including cervical cancer. Balstilimab is a novel, fully human monoclonal immunoglobulin G4 antibody, designed to block program cell death-1 (PD-1). Zalifrelimab is a novel, fully human monoclonal immunoglobulin G1 antibody, designed to block cytotoxic T-lymphocyte antigen-4 (CTLA-4).

Conditions

  • Cervical Cancer

Interventions

  • ZalifrelimabDrug

    Zalifrelimab was administered over 30 minutes and following the infusion of balstilimab.

  • BalstilimabDrug

    Balstilimab infusion was administered over 30 minutes.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 2: Objective Response Rate (ORR) - Independent Endpoint Review Committee (IERC)Time frame: Up to 2 years
  2. Phase 1: Number of Participants Experiencing Dose-limiting Toxicities (DLTs)Time frame: First 21 days of treatment

Locations

47 sites in 9 countries. Site status is shown where the registry gives one.

  • Comprehensive Care and Research Center

    Goodyear, Arizona

  • City of Hope National Medical Center

    Duarte, California

  • University of Miami

    Miami, Florida

  • BRCR Medical Center, Inc

    Plantation, Florida

  • Augusta University

    Augusta, Georgia

  • Cancer Treatment Centers of America

    Zion, Illinois

  • Ochsner Cancer Institute

    New Orleans, Louisiana

  • West Michigan Cancer Center

    Kalamazoo, Michigan

  • University of Oklahoma

    Oklahoma City, Oklahoma

  • Chattanooga's Program In Women's Oncology

    Chattanooga, Tennessee

  • CliniCore International

    Baytown, Texas

  • Providence Regional Cancer System

    Aberdeen, Washington

  • Swedish Cancer Institute

    Seattle, Washington

  • Mater Research

    South Brisbane, Australia

  • Icon Cancer Care South Brisbane

    South Brisbane, Australia

  • Scientia Clinical Research

    Sydney, Australia

  • Linear Clinical Research

    Perth, Western Australia, Australia

  • Clínica de Pesquisas e Centro de Estudos em Oncologia Ginecológica e Mamária Ltda.

    São Paulo, Brazil

  • IBCC - Instituto Brasileiro de Controle do Câncer

    São Paulo, Brazil

  • LLC Arensia Exploratory Medicine

    Tbilisi, Georgia

  • Magyar Honvedseg Egeszsegugyi Kozpont

    Budapest, Hungary

  • Orszagos Onkologiai Intezet

    Budapest, Hungary

  • Debreceni Egyetem

    Debrecen, Hungary

  • Bacs-Kiskun Megyei Korhaz

    Kecskemét, Hungary

  • Pecsi Tudomanyegyetem

    Pécs, Hungary

  • Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpont

    Szeged, Hungary

  • Jasz-Nagykun-Szolnok Megyei Hetenyi Geza Korhaz-Rendelointezet

    Szolnok, Hungary

  • Zala Megyei Szent Rafael Korhaz

    Zalaegerszeg, Hungary

  • ARENSIA Exploratory Medicine Unit, Institute of Oncology

    Chisinau, Moldova

  • BioResearch Group SP. Z O.O.

    Nadarzyn, Poland

  • Centrum Onkologii-Instytut im.M.Sklodowskiej Curie

    Warsaw, Poland

  • ICO l'Hospitalet - Hospital Duran i Reynals

    L'Hospitalet de Llobregat, Spain

  • START Madrid. Oncology Phase I

    Madrid, Spain

  • Hospital Universitario La Paz

    Madrid, Spain

  • Clinica Universidad de Navarra

    Pamplona, Spain

  • Hospital Universitario Virgen Macarena

    Seville, Spain

  • Hospital Universitari i Politecnic La Fe

    Valencia, Spain

  • CI Dnipropetrovsk CMCH #4 of Dnipropetrovsk RC Dept of Chemotherapy SI Dnipropetrovsk MA of MOHU

    Dnipro, Ukraine

  • CI Transcarpathian Cl Onc Center Dep of Surgery #1 SHEI Ivano-Frankivsk NMU

    Ivano-Frankivsk, Ukraine

  • Communal Non-profit Enterprise Regional Center of Oncology

    Kharkiv, Ukraine

Showing 40 of 47 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.